Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: Encouraging results of a phase II study

Sylvie Bonvalot, Thierry De Baere, Jean Mendiboure, Angelo Paci, Françoise Farace, Laurence Drouard-Troalen, Laure Bonnet, Antoine Hakime, Guillaume Bonniaud, Bruno Raynard, Philippe Israel, Axel Le Cesne, Alexander M. Eggermont, Agnès Laplanche, Jane Muret

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

22 Citaten (Scopus)


Purpose: To assess the efficacy of isolated pelvic perfusion (IPP) with tumor necrosis factor (TNF)-α and melphalan in patients with locally advanced cancers in the pelvic and groin area requiring mutilating surgery. Methods: A total of 27 patients were enrolled (carcinoma, n = 17; sarcoma/melanoma, n = 4; and endocrine tumor, n = 6). They were candidates for exarticulation (n = 3) or exenteration (n = 11) or were judged unresectable (n = 13). In installing IPP, tourniquets were positioned around both thighs, and an inflated pressure suit was placed at a subthoracic position. Tumor necrosis factor-α (300 μg) was injected in the perfusate, followed 5 minutes later by melphalan at 1.5 mg/kg. After 30 minutes, the remaining drugs were washed out. Leakage was assessed with technetium Tc 99m radiolabeled human serum albumin, and a pharmacokinetic study was performed. Efficacy was based on the complete response rate observed on magnetic resonance imaging. Results: Pelvic/systemic ratios of melphalan/TNF/technetium Tc 99m were 14.2/7/3.6. Responses on magnetic resonance imaging were as follows: 30% complete, 30% partial, 19% no change, and 15% progression. Two patients were not evaluable because they did not receive the treatment. Pre-IPP/post-IPP median percentage of necrosis on magnetic resonance imaging was 10%/70%. Median follow-up was 43 months. Median overall survival was 17 months. Twelve-month survival rate, disease-free survival, and local and metastatic recurrence rates were 67%, 30%, 57%, and 26%, respectively. Conclusions: Isolated pelvic perfusion with TNF-α compares favorably with historical data, as it was observed in limb perfusion and could provide a chance to translate its successful combination with chemotherapy into treatment of locally advanced pelvic cancers.

Originele taal-2Engels
Pagina's (van-tot)281-286
Aantal pagina's6
TijdschriftAnnals of Surgery
Nummer van het tijdschrift2
StatusGepubliceerd - feb. 2012
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: Encouraging results of a phase II study'. Samen vormen ze een unieke vingerafdruk.

Citeer dit